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Abstract 
Cystic and bile duct dysplasia is a rare histological finding, especially when found in the ab-
sence of an underlying malignancy. We report a patient who presented with jaundice and 
weight loss. Clinical and cytological evidence suggested a diagnosis of cholangiocarcinoma 
and the patient underwent a pancreatico-duodenectomy. Histopathological examination 
suggested a diagnosis of two foci of biliary dysplasia: cystic duct and lower common bile 
duct. Fifteen months later, the patient re-presented with signs of obstructive jaundice and 
biliary sepsis. Although CT scan revealed images highly indicative of metastatic disease, re-
peated biopsies failed to confirm this. Eventually a liver biopsy did reveal moderately differ-
entiated adenocarcinoma, however oncological interventional was no longer appropriate and 
the patient was managed palliatively. This case report focuses on the current understanding 
of progression of biliary dysplasia. © 2014 S. Karger AG, Basel 
Introduction 
Dysplasia is defined as an abnormality of cellular growth and development. An increase 
in cellular proliferation is associated with a reduced rate of apoptosis, while morphological 
features include hyperchromasia and pleomorphism. Dysplasia is classified histopathologi-
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cally as either low- or high-grade according to the degree of cytological abnormalities and 
cellular pleomorphism [1]. As dysplastic cells do not invade the basement membrane, the 
term ‘in situ neoplasia’ is often used synonymously and is considered a pre-cancerous state. 
In general, dysplasia is typically detected incidentally or as part of a screening investiga-
tion. With regard to ductal dysplasia, abnormalities, whether they be clinical, biochemical or 
radiological, will only be detectable if the lesion begins to occlude the lumen of the duct and 
therefore disrupt the normal function. In the context of the biliary ducts, disruption of nor-
mal luminal flow of bile can lead to obstructive jaundice [2]. 
Bile ductal dysplasia may represent a risk factor for the development of an invasive 
neoplasm at the same site. In this case, early detection of dysplastic cells at the duct margins, 
for example following a routine cholecystectomy, would allow more radical surgery to be 
performed early. This could, in theory, prevent the future development of an invasive 
carcinoma. Secondly, ductal dysplasia may be a risk factor for the development of malignan-
cy at another site within the ductal tree, suggesting predisposition to neoplastic transfor-
mation as a field event. Lastly, and more commonly, ductal dysplasia is seen as a local 
extension of an existing invasive cancer. Observational studies have shown that high-grade 
cystic duct dysplasia is present at the margins of resected cholangiocarcinomas in up to 13% 
of cases [3]. Importantly, however, this appears to have no effect on overall survival, al-
though there are higher rates of recurrence in long-term survivors. 
Case Report 
A 67-year-old gentleman was referred to the hepatobiliary surgical team after present-
ing to his general practitioner with features of obstructive jaundice-associated anorexia and 
weight loss of approximately 10 kg over a period of several months. Initial blood tests 
revealed a picture indicative of biliary obstruction: a raised serum bilirubin of 93 μmol/l, a 
serum aspartate aminotransferase (AST) of 50 IU/l and a serum alkaline phosphatase (ALP) 
of 454 IU/l. An ultrasound scan confirmed biliary obstruction characterised further by a CT 
scan as an intraluminal filling defect within the mid common bile duct (fig. 1a). Cellular 
brushings obtained during endoscopic retrograde cholangiopancreatography and biliary 
stenting demonstrated high-grade dysplastic cells but no evidence of invasive malignancy. 
Following a multi-disciplinary team meeting a provisional diagnosis of cholangiocarcinoma 
was made and the patient underwent pylorus-preserving pancreatoduodenectomy with 
Roux-en-Y reconstruction, pancreatojejunostomy, hepaticojejunostomy and gastrojejunos-
tomy. Histological examination of the surgical specimen however did not reveal invasive 
malignancy but rather two foci of high-grade biliary dysplasia in the cystic duct and in the 
intrapancreatic segment of the common bile duct (fig. 1b). The post-operative period was 
complicated by a low-volume pancreatic leak which led to sepsis. The patient’s blood results 
were as follows: a haemoglobin (Hb) level of 8.5 g/dl, a white cell count of 21.3 × 109/l, a 
neutrophil count of 18.1 × 109/l and a platelet count of 293 × 109/l. The patient had a 
bilirubin of 31 μmol/l, an AST of 45 IU/l and an ALP of 63 IU/l. C-reactive protein was 73 
mg/l. The patient was managed conservatively with pleural and peritoneal drain placement 
percutaneously. Gastroparesis required the placement of a nasojejunal tube for feeding. 
These post-operative complications necessitated an in-patient stay of nearly 3 weeks. The 
patient was discharged with a normal full blood count and normalising liver function tests. 
One week post-discharge the patient presented to the emergency department with 
haematemesis and collapse. On examination he was haemodynamically unstable with a Hb 
level of 5 g/dl and platelets of 113 × 109/l. He was transfused with packed red blood cells, 
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platelets and coagulation products and managed on the intensive care unit. Angiogram 
revealed a gastro-duodenal artery stump haemorrhage, which was treated with a covered 
stent over the origin of the gastro-duodenal artery (fig. 1c). Subsequently, for the first time, 
the patient manifested with bile leak from the old drain site. This was treated with a re-
trievable covered stent across the hepaticojejunostomy under percutaneous transhepatic 
cholangiography (fig. 1d), CT-guided drainage of the collection and broad-spectrum anti-
biotics. Enterococcus faecalis was managed with appropriate antibiotics. The patient was fit 
for discharge 4 weeks later. He did not undergo surveillance or chemotherapy as no invasive 
cancer was diagnosed. 
After an uneventful and complication-free period of 14 months, the patient presented to 
the emergency department with jaundice and biliary sepsis. Liver function tests on admis-
sion showed a bilirubin of 54 μmol/l, an AST of 52 IU/l and an ALP of 320 IU/l. C-reactive 
protein was 91 mg/l. A CT scan revealed a large 9-cm central soft tissue mass in segment 
V/VIII of the liver, at the confluence of the right and left biliary trees, and multiple smaller 
liver lesions, an appearance highly suggestive of metastatic disease (fig. 2a). However, no 
evidence of malignancy was obtained from a targeted ultrasound-guided liver biopsy and the 
patient was therefore treated with antibiotics, percutaneous transhepatic cholangiogram 
and biliary drains (fig. 2b, c). Repeat CT showed no change in appearance of the liver lesions, 
therefore ruling out abscess. After nearly 2 months following the previous biopsy, the pa-
tient attended electively for a check cholangiography, repeat biliary stenting and a repeat 
liver biopsy. This biopsy showed moderately differentiated adenocarcinoma, in keeping with 
a metastatic cholangiocarcinoma (fig. 2d). Re-assessment of pancreatico-duodenectomy 
specimen with multiple levels failed to reveal any focus of invasive cancer. On follow-up 
assessments the patient’s liver function tests continued to deteriorate, with a bilirubin of 
234 μmol/l, an alanine aminotransferase of 80 IU/l, an AST of 200 IU/l, an ALP of 364 IU/l 
and a gamma-glutamyl transferase of 563 IU/l. The patient was referred for palliative care  
as he was unfit for chemotherapy. He unfortunately died secondary to biliary sepsis several 
weeks later. 
Discussion 
Considering that a tissue diagnosis of malignancy was eventually made, it may be worth 
delineating the potential relevance of the original presence of cystic duct dysplasia. The 
cystic duct dysplasia may have either represented a pathological state from which the 
eventual adenocarcinoma directly originated or one which shared common risk factors, such 
that the presence of dysplastic cells forecasts the development of malignant cells at an in-
dependent site. As the pylorus-preserving pancreatoduodenectomy specimen showed no 
malignant cells, it is unlikely that the cystic duct dysplasia represented a local extension of 
an existing carcinoma. 
There is very little literature on the prevalence, aetiology or management of cystic duct 
dysplasia and the associated incidence of cholangiocarcinoma. Cholangiocarcinoma is a rare 
diagnosis [4]. Bile duct carcinoma is frequently associated with dysplasia and is multifocal in 
10% of cases [5]. Cystic duct dysplasia may therefore be associated with an underlying bile 
duct carcinoma. To date, only one case series has been published interrogating the presence 
of cystic duct dysplasia in the absence of existing carcinoma [6]. This study identified only  
4 patients with cystic duct dysplasia from a total of 193 who underwent cholecystectomies 
with cancer-free specimens. A recent study from our institution demonstrated that up to 
2.8% of patients might have incidental gall bladder dysplasia or carcinoma [7]. 
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The risk factors for the development of cystic duct dysplasia remain incompletely un-
derstood much the same as invasive cholangiocarcinomas. Several studies have suggested 
that hepatitis C virus and alcohol may represent aetiological factors [8]. We have suggested 
that gall bladder dysplasia is more common in older patients and those with Asian ethnicity 
[7]. Several potential disease markers have been investigated. For example, expression of the 
oncofetal protein IMP3 (insulin-like growth factor II mRNA-binding protein 3) was found to 
correlate with increased tumour aggressiveness and reduced overall survival [9]. 
The case presented above posed several dilemmas regarding management decisions, 
including management of complications post-pancreatico-duodenectomy and surveillance of 
patients with dysplasia. The authors suggest a tailored approach for each patient in the ab-
sence of any longitudinal case-control or cohort studies. Currently there is no evidence for 
chemotherapy for dysplasia in the absence of invasive malignancy. 
Based on clinical experience and the few published reports available, cystic duct dyspla-
sia is certainly a rare condition, but one that warrants further investigation. It is worth not-
ing that, despite the progression of pathology demonstrated in the above case and although 
dysplasia is generally considered a precursor to malignancy, not all dysplastic lesions ulti-
mately develop malignancy. A small minority may remain unchanged in size for years and 
yet others may even disappear [10]. The authors suggest that high-grade biliary dysplasia be 
put on a surveillance programme in much the same way as invasive cholangiocarcinoma. If 
all the clinical and radiological clues point towards malignancy, treatment such as chemo-
therapy should be initiated even if a histological diagnosis cannot be confirmed. A more 
conservative management could leave the patient at risk. 
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Fig. 1. Initial presentation and treatment with management of complications. 
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Fig. 2. Re-presentation with advanced cancer. 
 
